We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OPTX:NASDAQSyntec Optics Holdings, Inc. Analysis

Data as of 2026-05-19 - not real-time

$6.55

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Syntec Optics is trading at $6.55, well below its 20‑day ($8.09) and 50‑day ($8.20) SMAs, indicating short‑term weakness, while still above the 200‑day SMA ($4.30) and hovering near the calculated support of $6.32. RSI sits at 41, suggesting the stock is not yet oversold, but the MACD histogram is negative and the signal line is bearish, reinforcing downward momentum. Volume has been trending down, and the 30‑day volatility of roughly 149% combined with a beta of 3.4 points to extreme price swings. The DCF‑derived fair value of $0.06 is a fraction of the current price, flagging the stock as dramatically overvalued. On the fundamentals side, revenue fell 8% year‑over‑year, margins are negative (operating –12%, profit –11%), and the company carries $11.2 M of debt against only $0.6 M of cash, yielding a debt‑to‑equity of 129%. The price‑to‑book ratio of 25× and price‑to‑sales of 9.5× further underscore the valuation disconnect, while ROE and ROA are deep in negative territory. No dividend is paid, and the payout sustainability is therefore false. Recent news reports a $20 M underwritten public offering and a milestone of quadrupling monthly production in March 2026, which may provide short‑term liquidity and operational optimism but also dilute existing shareholders. The market sentiment index reads “Extreme Greed,” reflecting speculative enthusiasm despite the weak fundamentals. Overall, the technical picture is bearish, the valuation is stretched, and the balance sheet is fragile, making the near‑term outlook challenging.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Price below short‑term moving averages
  • Bearish MACD and decreasing volume
  • Severe overvaluation relative to DCF

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Recent production ramp‑up indicating operational improvement
  • Equity raise provides cash but adds dilution
  • Continued negative earnings and high debt load

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Fundamental turnaround required to justify valuation
  • Potential defense and medical market tailwinds
  • Persistent volatility and high beta

Key Metrics & Analysis

Financial Health

Revenue Growth-7.90%
Profit Margin-10.95%
ROE-30.03%
ROA-4.57%
Debt/Equity129.03
P/B Ratio25.2
Op. Cash Flow$843.0K
Free Cash Flow$1.0M
Industry P/E38.2

Technical Analysis

TrendNeutral
RSI41.2
Support$6.32
Resistance$11.46
MA 20$8.09
MA 50$8.20
MA 200$4.30
MACDBearish
VolumeDecreasing
Fear & Greed Index89.45

Valuation

Fair Value$0.06
GradeOvervalued
TypeValue

Risk Assessment

Beta3.41
Volatility149.35%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.